Larouche, Miriam
Khoury, Etienne
Brisson, Diane
Gaudet, Daniel
Article History
Accepted: 21 November 2023
First Online: 14 December 2023
Declarations
:
: The authors declare no competing interests.
: DG <i>Employer</i>: Université de Montréal; <i>Consultation fees:</i> Amryt (Chiesi), Arrowhead, CRISPR Therapeutics, Eli Lilly, Ionis, Pfizer, Regeneron; <i>Trust research/joint research funds (trials):</i> Arrowhead, Eli Lilly, Ionis, Kowa, Pfizer, Regeneron<b>.</b> ML, EK, and DB have nothing to disclose.
: This article does not contain any studies with human or animal subjects performed by any of the authors.